JZJia Zhang

Jia Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia Zhang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Qiguo Xiao

    Department of Ophthalmology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

    6 shared publications
  • Jing Lu

    4 shared publications
  • Weijie Jiang

    The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China

    4 shared publications
  • Siqi He

    The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China

    3 shared publications
  • Fangfang Lu

    Department of Ophthalmology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China

    2 shared publications
  • Fangfang Lu

    State Key Laboratory of Ophthalmology; Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science; Guangdong Provincial Clinical Research Center for Ocular Disease, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

    2 shared publications

Latest Publications

  • Open Access

    ApoE is associated with retinal inflammation during the progression of retinitis pigmentosa

    by Baiyi Gu, Jing Lu, Weijie Jiang, Shigang Xia, Zhi Wang, Lin Ling, Qiguo Xiao, Jia Zhang

  • Open Access

    Trends, hotspots, and future directions of inflammation in age-related macular degeneration: A 20-year bibliometric study

    by Fangfang Lu, Jia Zhang, Jing Msc Lu, Weijie Bsc Jiang, Zhigang Msc Fei, Qiguo Xiao, Zhi Wang

    Background: Inflammation significantly impacts the pathogenesis of age-related macular degeneration (AMD), the primary cause of vision loss in the elderly. With the aging global population and increasing incidence of AMD, understanding the inflammation-related mechanisms and identifying potential therapeutic targets have become paramount. This study aims to offer a bibliometric analysis of global research contributions focused on inflammation in AMD, shedding light on research trends, collaborations, and future directions. Methods: We retrieved publications related to inflammation in AMD from 2003 to 2023 from the Web of Science Core Collection database. A total of 2044 articles were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to examine publication trends, influential countries, institutions, authors, and journals, as well as emerging research topics. Results: Our analysis revealed a steady global increase in annual publications. The United States and China emerged as leading contributors, demonstrating substantial collaboration and investment in AMD research. Among institutions, the National Eye Institute in the United States and the University of Eastern Finland stood out for their prolific contributions. Key researchers such as Kaarniranta have been central to advancing the field, offering potential collaboration opportunities. Investigative Ophthalmology and Visual Science and Experimental Eye Research were identified as the top journals publishing significant work on inflammation in AMD. Keywords such as “oxidative stress,” “complement” “autophagy,” “macrophage,” and “microglia” were frequently mentioned, highlighting these as current research hotspots. Conclusion: This analysis underscores the importance of inflammation in AMD and maps the evolution of research, suggesting future directions that may offer new therapeutic strategies.

  • Open Access

    Mechanisms of Mesenchymal Stem Cell‐Derived Exosomes in Dry Eye Disease: From Inflammation Pathways to Therapeutic Prospects

    by Jiahuan Yi, Fangfang Lu, Yale Tian, Yu Wang, Zihe Zhang, Xujie Deng, Zhi Wang, Shigang Xia, Jia Zhang, Qiguo Xiao

    Dry eye disease (DED) is a chronic ocular surface disorder triggered by tear film imbalance, in which inflammatory disruption of immune homeostasis constitutes the core pathological mechanism. Mesenchymal stem cell‐derived exosomes (MSC‐Exos) offer promising anti‐inflammatory therapeutic potential through immune modulation, tissue repair, and their inherently low immunogenicity. This review elucidates MSC‐Exos’ molecular regulation of DED inflammation, demonstrating their suppression of the TLR4/NF‐κB signaling axis, the IRAK1/TRAF6/NF‐κB cascade reaction, the STAT3 transcriptional regulatory network, and the NLRP3 inflammasome activation pathway, while revealing a synergistic mechanism through which MSC‐Exos ameliorate the ocular surface inflammatory microenvironment by modulating the Th17/Treg immune balance via the gut–eye axis and facilitating FBXW7‐mediated ubiquitination degradation pathways. Despite this therapeutic potential, clinical translation is hampered by exosomal heterogeneity, difficulties in standardization, and suboptimal delivery efficiency and long‐term efficacy. Future progress will require the integration of nanotechnology and gene editing to enhance therapeutic functionality, ultimately positioning MSC‐Exos as precision biologics for DED.

  • Open Access

    Uptake of Mesenchymal Stem Cell-Derived Exosomes in Mouse Brain through Intranasal Delivery

    by Zihe Zhang, Siqi He, Weijie Jiang, Jing Lu, Songbin Liu, Wenjun Xu, Zhi Wang, Fangfang Lu, Qiguo Xiao, Jia Zhang

    Introduction: Exosomes are nanoscale extracellular vesicles that widely participate in intercellular communication. An increasing number of studies have reported on the neuroprotective effects of stem cell-derived exosomes in brain diseases through various delivery methods. However, only a few reports are available on the delivery and uptake of stem cell-derived exosomes in the brains of mice of different ages. Methods: PKH-26-labelled mesenchymal stem cell-derived exosomes were collected, and their uptake was investigated in the brains of mice aged 2 weeks, 2 months, and >6 months, 24 hours after intranasal delivery. Results: No exosomes were distributed in the whole brains of 2-week-old mice after 24 hours of intranasal delivery. However, a small number of exosomes were found in the olfactory bulb, cortex, and hippocampus of 2-month-old mice, with no exosomes observed in the cerebellum. In contrast, a large number of exosomes were ingested in all brain regions, including the olfactory bulb, cortex, hippocampus, and cerebellum, of >6-month-old mice. Conclusion: Exosomes can enter the brains of adult mice through intranasal administration, but there are differences in the uptake rate among mice of different ages. These findings provide a theoretical basis for the future clinical administration of exosomes for treating brain disorders.


  • Open Access

    Clodronate liposome-mediated macrophage depletion ameliorates iron overload-induced dry eye disease

    by Jing Lu, Fangfang Lu, Zhengwu Peng, Zihe Zhang, Weijie Jiang, Xia Meng, Xin Yi, Tuo Chen, Zhigang Fei, Yu Wang, et al.


  • Potential Roles of Nr4a3-Mediated Inflammation in Immunological and Neurological Diseases

    by Siqi He, Weijie Jiang, Baoyi Jiang, Chunyan Yu, Guifang Zhao, Yifei Li, Ling Qi, Jia Zhang, Dan Wang

    As a protein of the orphan nuclear receptor Nr4a family, Nr4a3 has no identified natural ligands. However, its biological activity can be mediated by inducing conformational changes through interactions with specific certain small molecules and receptors. Nr4a3 is activated as an early stress factor under various pathological conditions and plays a regulatory role in various tissues and cells, participating in processes such as cell differentiation, apoptosis, metabolism, and homeostasis. At present, research on the role of Nr4a3 in the pathophysiology of inflammation is considerably limited, especially with respect to its role in the central nervous system (CNS). In this review, we discuss the role of Nr4a3 in multiple sclerosis, Alzheimer’s disease, retinopathy, Parkinson’s disease, and other CNS diseases. This review shows that Nr4a3 has considerable potential as a therapeutic target in the treatment of CNS diseases. We provide a theoretical basis for the targeted therapy of CNS diseases and neuroinflammation, among other conditions.


  • Open Access

    New insights on the role of microRNAs in retinal Müller glial cell function

    by Weijie Jiang, Siqi He, Logen Liu, Xia Meng, Jing Lu, Juan Li, Tuo Chen, Ying Xu, Qiguo Xiao, Ling Qi, et al.

    MicroRNAs belong to the family of non-coding RNAs that participate in cell proliferation, cell death and development. The Müller glial cells are the inherent and specific neuroglia cells in the retinal organisation and play significant roles in retinal neuroprotection, organisational maintenance, inflammation and immunity, regeneration, and the occurrence and development of retinal diseases. However, only a few studies report the underlying mechanism of how miRNAs drive the function of Müller glial cells in the development of retinal diseases. This review aims to summarise the roles of miRNAs in retinal Müller glial cell function, including gliogenesis, inflammation and immunity, regeneration, the development of retinal diseases, and retinal development. This review may point out a novel miRNA-based insight into retinal repair and regeneration. MiRNAs in Müller glial cells may be considered a diagnostic and therapeutic target in the process of retinal repair and regeneration.